Group of Translational ResearchDivision of Biomarker Discovery (Kashiwa)
- Aug. 31, 2020
- Update Publication list.
- Jan. 28, 2020
- Update member list and Publication list.
Personalized medicine means a therapy in which an appropriate treatment is provided to a patient based on the molecular characteristics of the patient and cancer tissues. Many newly-approved drugs include molecular targeting agents.
The Division of Biomarker Discovery TR (Translational Research) has been exploring new biomarkers which may enable the prediction of the prognosis of cancer patients and biological figures of cancer through clinical studies. It has been conducting companion diagnoses (CDX) with businesses in ISO 15189 approval pathology laboratory with the aim to achieve personalized medicine.
It is quite important to create biomarkers which enable the selection of appropriate cancer patients who may be enrolled in certain clinical studies as well as non-clinical studies. In this Division, novel biomarkers have been developed by combining histopathologic samples of cancer that are obtained from actual cancer patients with their blood and associated patient information, gene analyses, and various Omics information including metaborome analyses through collaborations with many external research institutes and drug discovery companies. This division aims to establish novel cancer therapy including the development of novel PDX (patient derived xenograft) technology and diagnostic methodology.
Particularly, our research is focused on the development of therapy based not only on the exploration of molecular markers produced by cancer cells but also on the novel molecular markers relating to the characteristic cancer microenvironment created by cancer cells and stroma cells, and the exploration of novel biomarkers that is built on the elucidation of the molecular mechanism of pain in cancer patients or cancer cachexia.